<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393117</url>
  </required_header>
  <id_info>
    <org_study_id>CASE10117</org_study_id>
    <nct_id>NCT03393117</nct_id>
  </id_info>
  <brief_title>Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Breast Recontruction</brief_title>
  <official_title>Prospective, Randomized, Blinded Comparison of Bupivacaine Versus Liposomal Bupivacaine For Breast Pain Management After Unilateral, Immediate Breast Reconstruction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the most effective way to control post-operative
      breast pain for patients undergoing a unilateral, immediate breast reconstruction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized controlled study to compare the effectiveness of a breast nerve block
      performed with bupivacaine as compared to liposomal bupivacaine in providing postsurgical
      analgesia in patients undergoing unilateral abdominally-based breast reconstruction at time
      of mastectomy.

      OBJECTIVES

        1. Compare the amount of postoperative narcotic use in patients receiving a bupivacaine or
           liposomal bupivacaine pectoralis and serratus anterior nerve block. Compare these groups
           to a retrospective control cohort who received local anesthetic infusion but did not
           receive any nerve block.

        2. Examine the incidence of narcotic-related side effects in the experimental groups by
           documenting incidents of nausea and vomiting, time to first ambulation, liquid and solid
           oral intake.

        3. Survey patient satisfaction with pain management using a visual analog scale during
           their hospital stay.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Medication utilized will be blinded in the chart per inpatient pharmacy.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>total post-operative narcotic utilization</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
    <description>post-operative pain as measured by total post-operative narcotic utilization standardized to milligrams of morphine.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>at rest pain score on visual analog scale</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
    <description>0-100 score of self-reported pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>coughing pain score on visual analog scale</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
    <description>0-100 score of self-reported pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of incidents of nausea reported by patient</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
    <description>self-report of nausea</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of incidents of vomiting reported by patient</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
    <description>number of times a patient vomits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first ambulation</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first liquid intake</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to first solid intake</measure>
    <time_frame>Up to 72 hours post-operative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Liposomal Bupivacaine + Bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This group will receive a long-acting pain medicine, Liposomal Bupivacaine, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bupivacaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive the same pain medication, Bupivacaine, but in the standard formulation, injected into the breast muscles during surgery. All patients will receive patient-controlled analgesia pump and oral narcotics as indicated post surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal Bupivacaine</intervention_name>
    <description>20mL vial of Liposomal Bupivacaine (266 mg). The infiltration technique for Liposomal Bupivacaine will be 80mL injected into either hemi-abdomen as a transversus abdominous plane (TAP) block via ultrasound guidance. The other 80mL will be utilized in the operative breast for the field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks.</description>
    <arm_group_label>Liposomal Bupivacaine + Bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>20mL vial of 0.25% Bupivacaine. The field blocks (20mL), pectoralis 1 (20mL), pectoralis 2 (20mL) and serratus anterior (20mL) blocks will be performed with 0.25% Bupivacaine.</description>
    <arm_group_label>Liposomal Bupivacaine + Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine</arm_group_label>
    <other_name>Sensorcaine-Methyl Paraben Free (MPF) Spinal</other_name>
    <other_name>Sensorcaine-MPF</other_name>
    <other_name>Sensorcaine</other_name>
    <other_name>ReadySharp Bupivacaine</other_name>
    <other_name>P-Care M</other_name>
    <other_name>Marcaine Spinal</other_name>
    <other_name>Marcaine Preservative Free</other_name>
    <other_name>Marcaine</other_name>
    <other_name>Bupivacaine Spinal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Patient-Controlled Analgesia Pump</intervention_name>
    <description>The patient-controlled anesthesia will be filled with morphine or hydromorphone. Pumps will be programmed be on demand only with no basal rate.</description>
    <arm_group_label>Liposomal Bupivacaine + Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine</arm_group_label>
    <other_name>intravenous narcotic</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral Narcotic</intervention_name>
    <description>Oral narcotics will be offered when the patient's diet is advanced as tolerated, typically post-operative day 1.</description>
    <arm_group_label>Liposomal Bupivacaine + Bupivacaine</arm_group_label>
    <arm_group_label>Bupivacaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients scheduled to have a unilateral, immediate breast reconstruction

        Exclusion Criteria:

          -  Pregnant

          -  Concurrent or recent medical condition that could interfere with study participation
             including:

               -  Hepatitis

               -  Alcohol/substance abuse

               -  Uncontrolled psychiatric disorders

               -  Known allergy

               -  Contraindication to amide-type local anesthetics, opioids, or propofol.

          -  Body weight of less than 50 kg

          -  Participated in another study involving an investigational medication within the prior
             30 days

          -  Taking analgesics (i.e., nonsteroidal anti-inflammatory drugs, acetaminophen, or
             opioids), antidepressants, or glucocorticoids within the 3 days before surgery.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Risal Djohan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Clinic, Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Risal Djohan, MD</last_name>
    <phone>440-878-2500</phone>
    <email>DJOHANR@ccf.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic, Case Comprehensive Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2017</study_first_submitted>
  <study_first_submitted_qc>January 5, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reconstruction</keyword>
  <keyword>Bupivacaine</keyword>
  <keyword>Liposomal Bupivacaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mastodynia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Narcotics</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

